Denosumab biosimilar - Fresenius Kabi
Alternative Names: FKS-518Latest Information Update: 15 Jul 2024
At a glance
- Originator Fresenius Kabi
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Bone disorders; Giant cell tumour of bone; Hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis